(18)F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer.
about
The use and misuse of positron emission tomography in lung cancer evaluationPositron emission tomography/computerized tomography in lung cancer.Comparison of squamous cell carcinoma and adenocarcinoma of the lung by metabolomic analysis of tissue-serum pairs.Primary analysis of the phase II component of a phase I/II dose intensification study using three-dimensional conformal radiation therapy and concurrent chemotherapy for patients with inoperable non-small-cell lung cancer: RTOG 0117.From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.Lung cancer 7: management of lung cancer in elderly patients.Impact of FDG-PET findings on decisions regarding patient management strategies: a multicenter trial in patients with lung cancer and other types of cancer.Correlating metabolic and anatomic responses of primary lung cancers to radiotherapy by combined F-18 FDG PET-CT imaging.Incidental gastrointestinal 18F-Fluorodeoxyglucose uptake associated with lung cancer.Prognostic Value of Baseline 18F-FDG PET/CT Functional Parameters in Patients with Advanced Lung Adenocarcinoma Stratified by EGFR Mutation Status.Reproducibility and uptake time dependency of volume-based parameters on FDG-PET for lung cancer.Should positron emission tomography/computed tomography be the first rather than the last test performed in the assessment of cancer?Impact of tumor size and tracer uptake heterogeneity in (18)F-FDG PET and CT non-small cell lung cancer tumor delineationA phase I trial of high-dose palliative radiotherapy plus concurrent weekly Vinorelbine and Cisplatin in patients with locally advanced and metastatic NSCLCImpact of staging with 18F-FDG-PET on outcome of patients with stage III non-small cell lung cancer: PET identifies potential survivors.Quality assurance of positron emission tomography/computed tomography for radiation therapy.The Pearl of FDG PET/CT in Preoperative Assessment of Patients with Potentially Operable Non-Small-Cell Lung Cancer and its Clinical Impact.Clinical oncologic applications of PET/MRI: a new horizon.The clinical significance and management of lesion motion due to respiration during PET/CT scanning.A Prospective Study Comparing Functional Imaging (18F-FDG PET) Versus Anatomical Imaging (Contrast Enhanced CT) in Dosimetric Planning for Non-small Cell Lung Cancer.Use of Positron Emission Tomography/Computed Tomography in Radiation Treatment Planning for Lung Cancer.Current concepts in F18 FDG PET/CT-based radiation therapy planning for lung cancer.Efficacy of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in evaluating lung cancer recurrence.(18)FDG PET-CT standardized uptake value for the prediction of radiation pneumonitis in patients with lung cancer receiving radiotherapy.PET/CT: will it change the way that we use CT in cancer imaging?Comparison of biological target volume metrics based on FDG PET-CT and 4DCT for primary non-small-cell lung cancer.The role of positron emission tomography in the diagnosis, staging and response assessment of non-small cell lung cancer.
P2860
Q27021838-1B3D4376-3832-4037-B0C7-B5FF91F5F0E3Q33657999-ED6118AC-B712-4AF1-9E01-612DAADA0DCEQ33712528-FE4B342C-9847-4EB6-963F-AC0431DBD809Q33897625-5E6F7CB4-6F90-4EB6-A7E8-888DE812CB05Q34978457-0C7D0196-5B97-42A7-9371-CF5C8842C45DQ35186819-9581D05F-6B2F-4D8E-8EFD-1D25D5BEE55EQ35783387-EF3FC517-7BDE-475A-A4E5-B2EE1FBDD8A8Q35843758-8794E9C2-EB39-44ED-B12D-C07FB81E7646Q35859364-39F4FA59-E74D-4AC4-9727-30CE4B5A3D71Q36060090-84DB37F6-0D43-413F-A789-A49C4E64EE0EQ36093008-966F0126-105D-4CE3-B664-C6204F5BD578Q36286485-F4E05DD9-6723-453B-A75C-27A016877BFEQ36350466-6B20F27F-723F-4ADD-B8A5-94DA4C5CF50FQ36615344-49DD984F-3517-4A34-8B71-F9988998528AQ36925028-4C57A5A6-277C-4C31-B667-F616A7E73216Q37011261-84F7618E-B56D-4A17-B97B-8A1843541CA0Q37649203-E99F0D51-0DF6-4F3E-A4F2-11579E5CA212Q37711076-98DBAE9A-D23E-4D9B-96EE-5956611AD90AQ37971475-6EC08412-A04C-467C-AE87-DB9B79E4BC4DQ41053874-DBCE4656-BC05-4C9D-9C42-87E4545CD1DCQ41677756-5252A2EA-B6C8-4E9C-B1E4-088916DD6CFCQ42232269-1452642E-6FFA-43B8-9DEC-44F55DEBD729Q42714896-A309537F-F7F2-477B-96D5-F9BF6B3E55C2Q42736347-467E523D-ED23-4F51-8B3A-3A316A62DF50Q42945884-929E5F09-34C8-418A-9465-E1D04EC66624Q47118767-DE9C3F09-F46F-4591-8994-4FC1861796A3Q55221692-467AFCCE-1221-42AB-8EC5-F254D9F9B9C1
P2860
(18)F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
(18)F-FDG PET provides high-im ...... ed non-small cell lung cancer.
@en
type
label
(18)F-FDG PET provides high-im ...... ed non-small cell lung cancer.
@en
prefLabel
(18)F-FDG PET provides high-im ...... ed non-small cell lung cancer.
@en
P2093
P1476
(18)F-FDG PET provides high-im ...... ed non-small cell lung cancer.
@en
P2093
MacManus MP
Matthews JP
McKenzie AF
P304
P407
P577
2001-11-01T00:00:00Z